Jason D Hill

US Patent:

7862995, Jan 4, 2011

Filed:

Sep 9, 2005

Appl. No.:

11/223700

Inventors:

Sarah S. Bacus - Hinsdale IL, US
Jason Hill - Chicago IL, US

Assignee:

Targeted Molecular Diagnostics - Westmont IL

International Classification:

C12Q 1/00
C12Q 1/68
G01N 33/53
G01N 33/48
A01N 37/18

US Classification:

435 6, 435 4, 435 71, 514 2, 702 19

Abstract:

The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

US Patent:

20090214576, Aug 27, 2009

Filed:

Mar 6, 2006

Appl. No.:

11/817956

Inventors:

Sarah Bacus - Hinsdale IL, US
Jason Hill - Chicago IL, US

Assignee:

TARGETED MOLECULAR DIAGNOSTICS, LLC - Westmont IL

International Classification:

C07K 19/00
C12N 5/06
A61K 38/16
A61P 35/00

US Classification:

4241781, 435375, 514 12

Abstract:

The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.

US Patent:

20090318346, Dec 24, 2009

Filed:

Feb 8, 2007

Appl. No.:

12/278751

Inventors:

Sarah S. Bacus - Hinsdale IL, US
Jason E. Hill - Hinsdale IL, US
Josef Yarden - Rehovot IL, US
Bose S. Kochupurakkal - Bangalore, IN

Assignee:

Targeted Molecular Diagnostics - Westmont IL
Yeda Research and Development Co., Ltd. - Rehovot

International Classification:

A61K 38/16
C07H 21/04
A61P 35/00
C07K 14/00
C12N 5/10
C12N 1/19
G01N 33/574

US Classification:

514 12, 536 231, 530350, 435325, 4352542, 435358, 435 723

Abstract:

A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors.

US Patent:

20120263707, Oct 18, 2012

Filed:

Jan 27, 2012

Appl. No.:

13/359755

Inventors:

Jason Hill - Chicago IL, US

Assignee:

Ligacept, LLC - Oak Brook IL

International Classification:

C07K 16/30
A61K 39/395
A61P 35/00
C12N 15/13

US Classification:

4241331, 5303873, 536 2353

Abstract:

Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

US Patent:

20150247135, Sep 3, 2015

Filed:

May 19, 2015

Appl. No.:

14/715710

Inventors:

Jason Hill - Chicago IL, US

Assignee:

LIGACEPT, LLC - Oak Brook IL

International Classification:

C12N 9/12

Abstract:

Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of Erb-B1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

US Patent:

20150118228, Apr 30, 2015

Filed:

Apr 25, 2013

Appl. No.:

14/396965

Inventors:

- Oak Brook IL, US
Jason E. Hill - Chicago IL, US

International Classification:

C12N 9/12
C07K 14/71

US Classification:

4241341, 435194, 536 232, 4353201, 435361, 424 945, 435328

Abstract:

A chimeric ErbB ligand binding molecule is disclosed along with its pharmaceutically acceptable salt forms. The molecule is a protein that as part of its sequence includes the sequence of SEQ ID NOS: 1, 2, or 3. The molecule can be fused to an IgGFc and especially IgGFc containing cysteine to serine changes in the hinge region. For example, the fusion can be to IgG 1Fc DNA sequences that encode the binding molecules are also contemplated as well as vectors containing such DNA sequences and hosts that contain such vectors. Pharmaceutical compositions are contemplated that contain the binding molecule along with a pharmaceutically acceptable excipient.